Von Wussow P - Search Results

1

Roferon (rIFN-alpha 2a) is more immunogenic than intron A (rIFN-alpha 2b) in patients with chronic myelogenous leukemia.

Von Wussow P, Hehlmann R, Hochhaus T, Jakschies D, Nolte KU, Prümmer O, Ansari H, Hasford J, Heimpel H, Deicher H. Von Wussow P, et al. J Interferon Res. 1994 Aug;14(4):217-9. doi: 10.1089/jir.1994.14.217. J Interferon Res. 1994. PMID: 7822880 Clinical Trial. No abstract available.

2

Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy.

von Wussow P, Jakschies D, Freund M, Deicher H. von Wussow P, et al. J Interferon Res. 1989 Sep;9 Suppl 1:S25-31. J Interferon Res. 1989. PMID: 2809276

3

Different specificities of SLE-derived and therapy-induced interferon-alpha antibodies.

Nolte KU, Jakschies D, Pestka S, Von Wussow P. Nolte KU, et al. Among authors: von wussow p. J Interferon Res. 1994 Aug;14(4):197-9. doi: 10.1089/jir.1994.14.197. J Interferon Res. 1994. PMID: 7822874 Clinical Trial. No abstract available.

4

Emergence and decay of the human Mx homolog in cancer patients during and after interferon-alpha therapy.

Jakschies D, Hochkeppel H, Horisberger M, Deicher H, von Wussow P. Jakschies D, et al. Among authors: von wussow p. J Biol Response Mod. 1990 Jun;9(3):305-12. J Biol Response Mod. 1990. PMID: 2380745

5

Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies.

Freund M, von Wussow P, Diedrich H, Eisert R, Link H, Wilke H, Buchholz F, LeBlanc S, Fonatsch C, Deicher H, et al. Freund M, et al. Among authors: von wussow p. Br J Haematol. 1989 Jul;72(3):350-6. doi: 10.1111/j.1365-2141.1989.tb07715.x. Br J Haematol. 1989. PMID: 2765403

6

[Exacerbation of psoriasis during alpha-interferon therapy].

Hartmann F, von Wussow P, Deicher H. Hartmann F, et al. Among authors: von wussow p. Dtsch Med Wochenschr. 1989 Jan 20;114(3):96-8. doi: 10.1055/s-2008-1066559. Dtsch Med Wochenschr. 1989. PMID: 2912680 German.

7

Intralesional interferon-alpha therapy in advanced malignant melanoma.

von Wussow P, Block B, Hartmann F, Deicher H. von Wussow P, et al. Cancer. 1988 Mar 15;61(6):1071-4. doi: 10.1002/1097-0142(19880315)61:6<1071::aid-cncr2820610603>3.0.co;2-t. Cancer. 1988. PMID: 3342367

8

Strong transient expression of the type I interferon-induced MxA protein in hepatitis A but not in acute hepatitis B and C.

Jakschies D, Zachoval R, Müller R, Manns M, Nolte KU, Hochkeppel HK, Horisberger MA, Deicher H, Von Wussow P. Jakschies D, et al. Among authors: von wussow p. Hepatology. 1994 Apr;19(4):857-65. Hepatology. 1994. PMID: 8138257

9

Epitopes recognized by neutralizing therapy-induced human anti-interferon-alpha antibodies are localized within the N-terminal functional domain of recombinant interferon-alpha 2.

Nolte KU, Günther G, von Wussow P. Nolte KU, et al. Among authors: von wussow p. Eur J Immunol. 1996 Sep;26(9):2155-9. doi: 10.1002/eji.1830260929. Eur J Immunol. 1996. PMID: 8814261

10

Correlation of the antiproliferative effect and the Mx-homologous protein induction by IFN in patients with malignant melanoma.

Jakschies D, Hochkeppel HK, Horisberger MA, Deicher H, von Wussow P. Jakschies D, et al. Among authors: von wussow p. J Invest Dermatol. 1990 Dec;95(6 Suppl):238S-241S. doi: 10.1111/1523-1747.ep12875854. J Invest Dermatol. 1990. PMID: 1701809 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

54 results

Search Page

Filters